Fulvestrant is a selective estrogen receptor degrader (SERD) used in the treatment of hormone receptor-positive metastatic breast cancer. It works by binding to estrogen receptors, blocking estrogen signaling, and promoting receptor degradation, thereby inhibiting tumor growth. Fulvestrant was first developed in the 1990s as a more effective alternative to existing anti-estrogen therapies like tamoxifen. Its development aimed to overcome resistance seen with earlier endocrine treatments. The drug received approval from the FDA in 2002 for use in postmenopausal women with advanced breast cancer. Fulvestrant is administered via intramuscular injection due to its poor oral bioavailability. Clinical trials demonstrated its efficacy both as a single agent and in combination with other targeted therapies. Over time, it has become an important option in managing hormone-driven breast cancers. The drug represents a shift toward more targeted endocrine therapies in oncology. Fulvestrant’s introduction marked a significant advancement in personalized cancer treatment strategies.
BRAND NAMES
Faslodex – this is the original and most widely recognized brand under which fulvestrant is marketed globally.
MECHANISM OF ACTION
Fulvestrant acts as a selective estrogen receptor degrader (SERD) by binding competitively to estrogen receptors in breast cancer cells, thereby blocking the natural hormone estrogen from attaching. In addition to this blockade, it promotes the breakdown and reduction of estrogen receptors within the cell, leading to a marked decrease in receptor levels.
PHARMACOKINETICS:
Absorption
Fulvestrant is administered as a long-acting intramuscular injection, typically into the gluteal muscle, rather than orally due to its poor gastrointestinal absorption.
Distribution
Fulvestrant has a very large apparent volume of distribution, estimated to be approximately 3–5 L/kg. This indicates extensive distribution beyond the bloodstream into body tissues, including adipose tissue and tumor sites.
Metabolism
Fulvestrant is extensively metabolized in the liver, primarily through Cytochrome P450 3A4 (CYP3A4)–mediated pathways. It undergoes oxidation, sulfonation, and conjugation to form multiple inactive metabolites.
Elimination
Fulvestrant is eliminated mainly via fecal excretion, with the majority of the dose recovered in feces as metabolites. Renal elimination is minimal, and only a very small fraction of the drug is excreted unchanged in urine.
PHARMACODYNAMICS
Fulvestrant is a selective estrogen receptor degrader (SERD) that acts by binding competitively to estrogen receptors and promoting their degradation. This leads to a reduction in estrogen receptor levels and complete inhibition of estrogen signaling pathways in hormone receptor–positive breast cancer cells.
ADMINISTRATION
Fulvestrant is administered as a deep intramuscular injection, usually into the gluteal muscles. It is not given orally due to poor bioavailability. The drug is typically used in postmenopausal women with hormone receptor–positive advanced or metastatic breast cancer, either as monotherapy or in combination with other targeted agents.
DOSAGE AND STRENGTH
Fulvestrant is commonly available in 250 mg/5 mL prefilled syringes. The standard recommended dose is 500 mg, administered as two 250 mg intramuscular injections. The dosing schedule typically includes:
Initial doses on day 1, day 15, and day 29
Followed by once monthly injections thereafter
DRUG INTERACTIONS
Fulvestrant has relatively few clinically significant drug interactions. Although it is metabolized by Cytochrome P450 3A4, it does not strongly inhibit or induce this enzyme, so interactions with CYP3A4 modulators are usually limited.
CONTRAINDICATIONS
Fulvestrant is contraindicated in patients with known hypersensitivity to fulvestrant or any of its formulation components. It is also contraindicated during pregnancy because of its mechanism of estrogen receptor blockade, which may cause fetal harm or developmental abnormalities.
SIDE EFFECTS
Injection site reactions (pain, swelling)
Hot flashes
Nausea
Fatigue
Headache
Musculoskeletal pain (joint or bone pain)
Elevated liver enzymes
OVER DOSAGE
There is limited clinical experience with overdose of fulvestrant. No specific antidote is available. In cases of overdosage, treatment is primarily symptomatic and supportive, focusing on monitoring vital signs and managing any emerging adverse effects.
TOXICITY
Fulvestrant is generally well tolerated, but toxicity may include liver dysfunction and, rarely, thromboembolic events. Because of its hormonal mechanism, it may also cause menopausal-like symptoms. Overdose data are limited, but adverse effects are expected to be an extension of its pharmacological action.
